Reveal Genomics and Ona Therapeutics join forces to advance next-generation cancer treatment

CAR-T Digest - August 2020

14 Apr 2025: Reveal Genomics and Ona Therapeutics join forces to advance next-generation cancer treatment

Reveal Genomics and Ona Therapeutics have formed a strategic partnership to accelerate the clinical development of ONA-255, a next-generation antibody-drug conjugate (ADC) targeting multiple solid tumors
Reveal Genomics will use advanced molecular and genomic analysis to support ONA-255’s precision targeting and effectiveness, enhancing understanding of its mechanism of action
Ona Therapeutics, in collaboration with Reveal Genomics’ U.S. subsidiary, has received a CDTI grant funded by the EU’s NextGenerationEU program to support the project
Both companies emphasize the importance of combining cutting-edge ADC design with advanced diagnostics to expand treatment options and improve outcomes for patients with aggressive cancers